As some FGF21-related candidate drugs, such as FGF21 analogs (Pegbelfermin, LY2405319, PF05231023) have been clinically tested to treat diabetes and other metabolic disorders, our findings strongly suggest that testing the efficacy of these FGF21 analogs in patients at high risk of VILI may be necessary. The gene discussed is FGF21; the disease is metabolic disease.